Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SKMEL-23 |
Human skin malignant metastatic melanoma cell line | Human | skin | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. Renziehausen et al., Oncogene, 2019, 38:2320–2336, doi.org/10.1038/s41388-018-0563-y | |||
SKMEL-224 |
Human skin malignant melanoma cell line | Human | skin | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. Renziehausen et al., Oncogene, 2019, 38:2320–2336, doi.org/10.1038/s41388-018-0563-y | |||
SkBr3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | N. Golkar et al., Int. J. of Pharmaceutics, 2016, 510: 30-41; doi.org/10.1016/j.ijpharm.2016.06.026 | ||
SkBr3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | N. Golkar et al., Data in Brief, 2016, 8:1018-1023; doi.org/10.1016/j.dib.2016.06.064 | Link | |
SK-N-SH |
Human neuroblastoma cell line | ATCC HTB-11 | Human | brain | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | Z. Ping et al., Cell Cycle, 2012, 11: 10, 1999-2005, doi.org/10.4161/cc.20402 | Link | |
SK-N-BE(2) |
Human neuroblastoma cell line | ATCC CRL-2271 | Human | brain | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. Bertoni et al., J. Biol. Chem., 2011, 286 (6): 4727–4741, DOI 10.1074/jbc.M110.156521 | Link | |
SK-MEL-3 |
Human skin malignant metastatic melanoma cell line | ATCC HTB-69 | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | S. Romano et al., Pigment Cell Melanoma Res., 2013, 26: 900–911, doi: 10.1111/pcmr.12144 | ||
SH-SY5Y |
Human neuroblastoma cell line | ATCC CRL-2266 | Human | bone | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | S. Kim et al., Mol. Cell Biol., 2015, 35:1754-1762; doi:10.1128/MCB.01325-14 | Link | |
SH-SY5Y |
Human neuroblastoma cell line | ATCC CRL-2266 | Human | bone | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | K. Wanget al., Cell Mol. Neurobiol., 2016, 36:603-611; DOI 10.1007/s10571-015-0241-3 | ||
SAN |
Human lymphonodal melanoma cell line | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | S. Romano et al., Clinical and Translational Medicine, 2014, 3:1, doi:10.1186/2001-1326-3-1 | Link | ||
SAN |
Human lymphonodal melanoma cell line | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | S. Romano et al., Pigment Cell Melanoma Res., 2015, 28; 442-452; doi: 10.1111/pcmr.12378 | |||
SAN |
Human lymphonodal melanoma cell line | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | S. Romano et al., Cell Death and Disease, 2013, 4: e578, doi:10.1038/cddis.2013.109 | Link | ||
SAN |
Human lymphonodal melanoma cell line | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | S. Romano et al., Pigment Cell Melanoma Res., 2013, 26: 900–911, doi: 10.1111/pcmr.12144 | |||
RKO |
Human colon carcinoma cell line | ATCC CRL-2577 | Human | digestive organs | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M. Alagoz et al., Nucleic Acids Res., Mar 2014; 42: 3089 - 3103 | Link | |
Rat VSMC |
Rat (Wistar) vascular smooth muscle cells from thoracic aorta | Rat | vasculature | unknown | siRNA | RNA-Interference | Metafectene | publication | A. Giordano et al., Am J Physiol Heart Circ Physiol, Jun 2006; 290: H2459 - H2465 | Link | |||
Rat DRG neurons |
Rat neurons isolated from the DRG | Rat | nervous system | primary cell | adherent | siRNA | RNA-Interference | Metafectene | publication | C. Li et al., J. of Neuroinflammation, 2014, DOI 10.1186/s12974-015-0286-8 | |||
PM-WK |
Human skin malignant melanoma cell line | ATCC CRL-2624 | Human | skin | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. Renziehausen et al., Oncogene, 2019, 38:2320–2336, doi.org/10.1038/s41388-018-0563-y | ||
PC-3M |
Human prostate carcinoma cell line | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. L. Omara-Opyene et al., Lab Invest., 2004 Jul; 84(7):894-907 | |||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | application note | ![]() |
||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | U. Weirauch et al., Nucleic Acid Therapeutics, 2013, 23 (4): 264-272, DOI: 10.1089/nat.2012.0407 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | U. K. Mukhopadhyay et al., Cancer Res., Apr 2005; 65: 2872 - 2881 | Link | |
pBAEC |
Bovine primary aortic endothelial cells | Cow | vasculature | primary cell | adherent | siRNA | RNA-Interference | Metafectene | publication | Y. Riahi et al., Diabetes, Apr 2010; 59: 808 - 818 | Link | ||
P skin fibroblasts |
Human immortalized skin fibroblasts (patient derived) | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | C. Benincá et al., J. Med. Genet., 2021, 58: 155–167, doi:10.1136/jmedgenet-2020-106861 | Link | ||
NLF |
Human neuroblastoma cells | Human | unknown | unknown | plasmid | RNA-Interference | Metafectene | publication | S. Vomund et al., Cereb Cortex, Mar 2016; 10.1093/cercor/bhw060 | Link | |||
NLF |
Human neuroblastoma cell line | Human | unknown | cell line | plasmid | RNA-Interference | Metafectene | publication | S. Vomund et al., Cerebral Cortex,March 2017, 27: 2052-2063 | Link |